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Jæger GT, Larsen S, Moe L: Stratiﬁcation, Blinding and Placebo Effect in a Ran-
domized, Double Blind Placebo-controlled Clinical Trial of Gold Bead Implanta-
tion in Dogs with Hip Dysplasia. Acta vet. Scand. 2005, 46, 57-68. – The purpose of
this study was to investigate the need for and choice of stratiﬁcation factors, and the ef-
fects of blinding and placebo in a clinical experiment. Eighty dogs with canine hip dys-
plasia (CHD) were included in a randomized, placebo-controlled and double blind clin-
ical trial with stratiﬁed parallel group design, in which body weight and degree of CHD
were used as stratiﬁcation factors. Thirty-eight dogs were allocated to gold bead im-
plantation and 42 to placebo. After six months, 33 of the 42 placebo-treated dogs re-
ceived gold bead implantation in an open study lasting a further 18 months. The main
outcome variable in the study was change in pain signs of CHD as assessed by the
owner. No signiﬁcant difference in the main outcome variable, regardless of the treat-
ment given, could be detected in the two chosen stratiﬁcation factors. The only factor to
inﬂuence the main outcome variable signiﬁcantly was age. The blinding procedure used
in the study, in which 60% of the owners correctly guessed the treatment given, was
found sufﬁcient. Of those who guessed the treatment erroneously, 88% believed the
treatment given was gold bead implantation. The treatment efﬁcacy after six months in
the blinded treatment group was found to be signiﬁcantly larger compared to the efﬁ-
cacy obtained in the open study. A signiﬁcant placebo effect was therefore detected.
Conclusion and Clinical Relevance: The age of the dogs inﬂuenced the outcome of the
CHD treatment, and is recommended as a stratiﬁcation factor. A signiﬁcant placebo ef-
fect has to be expected and an optimal blinding procedure is necessary in similar clini-
cal studies.
canine; study design; hip dysplasia.
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Introduction
Different treatments for canine hip dysplasia
(CHD) have been described, with variable suc-
cess. Durkes (1992) suggested that the implan-
tation of gold beads at speciﬁc acupuncture
points in dogs with chronic pain due to hip dys-
plasia seemed promising. 
During the planning of a clinical therapy trial
with implantation of gold beads in CHD, no in-
formation on the most suitable stratiﬁcation
factors could be found in the published litera-
ture. While CHD is a very common disorder in
dogs and a large number of publications exists
on its etiology, risk factors for development,
breed prevalence, diagnostic methods, impor-
tance of prognostic factors for the development
of coxarthrosis, and different therapeutic meth-ods, good methodological studies of factors in-
ﬂuencing treatment outcome are lacking.
During statistical analysis of treatment results,
it is highly desirable to have as equal groups as
possible regarding both the patient characteris-
tics and diagnosis of disease. Although meth-
ods of statistical analysis exist to compensate
for unequal treatment groups, it is more con-
vincing to present data from equivalent groups,
and stratiﬁcation is a method for equalizing
treatment groups (Meinert 1986, Pocock 1983).
If we know the factors that may inﬂuence the
outcome of a speciﬁc treatment, we may need to
stratify for those factors. Sometimes the same
factor that causes a disease may inﬂuence the
outcome of treatment. However, the etiological
factors are often different from the stratiﬁcation
factors that affect the results of treatment. In
CHD, heredity is an important etiologic factor,
but is not necessarily a factor that affects the
outcome of a hip dysplasia treatment. When
comparing small treatment groups of up to 50
dogs, it is important to eliminate or balance the
factors that inﬂuence the outcome (Peto et al.
1976, Meinert 1986). 
How can stratiﬁcation factors be identiﬁed? In
smaller studies, this can be done by surmising
all factors that could possibly inﬂuence the out-
come of the treatment. The number of such fac-
tors may be large and the choice may be difﬁ-
cult. To stratify the animals on too many factors
will result in many groups with few cases each.
Consideration of earlier published trials or re-
lated experiments may also indicate one or
more factors that may affect treatment out-
come. Former treatment trials of CHD with
published stratiﬁcation factors were not found,
although a related study of risk factors for de-
generative joint disease associated with hip
dysplasia found that body weight and hip joint
laxity were such risk factors (Smith et al. 2001).
It may be of psychological beneﬁt if the person
reporting the treatment effect knows that the
animal is receiving a new treatment. In contrast,
owners that know their animal is on a standard
treatment may react unfavorably if they are
made aware that other patients are "privileged"
by receiving a new therapy. Such attitudes to-
wards the given therapy may affect the owner's
co-operation in a study, and may also inﬂuence
the reported efﬁcacy of the given treatment and
any comparison of treatments in a controlled
clinical trial (CCT) in animals, or may be dis-
torted if the patient or animal owner, or those
responsible for treatment and evaluation, know
which treatment is being used. This problem
can be avoided by performing a double blind
trial, in which neither patient or owner nor
physician or veterinarian are aware of which
treatment the patient or animal is receiving. The
ﬁrst study to include blinding in CCT seems to
have been published in 1927, and concerned
vaccines for the common cold (Ferguson et al.
1927). In the ﬁrst reported experiments with
control groups (Ferguson et al. 1927, Lind
1757), the allocation to treatment was arbitrary
or simply decided by the investigator. 
Any blinded and balanced CCT should include
an investigation of a possible placebo effect. A
placebo effect is any medical intervention that
has a favorable, non-speciﬁc, psychological, or
psycho-physiological therapeutic effect, but
without speciﬁc activity for the condition being
treated. This non-speciﬁc effect may also be
negative, that is, unfavorable (McMillan 1999),
in which case it is called a nocebo effect. To the
best of the authors' knowledge, Haygarth
(1800) performed the ﬁrst placebo CCT in 1799
and described the placebo effect for the ﬁrst
time. Placebo effects are commonly reported in
CCT studies where humans are involved. In ad-
dition to Pavlov's morphine experiments on
dogs (Pavlov 1927), one of the ﬁrst to describe
this effect in animals was Herrnstein (1962),
who injected scopolamine hydrobromide to
laboratory rats and demonstrated that saline in-
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drug. Other studies of conditioning placebo re-
sponses have been performed in animals (New-
ton & Ehrlich 1969, Riley 1981). 
However, the prime reason for introducing
placebo controls is to distinguish between the
effect caused by an active treatment, and other
effects due to reasons not related to the active
treatment. A possible placebo effect was dis-
cussed in a study of gold wire implants in CHD
where an equal improvement in locomotion and
pain as evaluated by owners was found in both
the placebo and treatment groups (Hielm-
Bjorkman et al. 2001). A placebo effect in com-
panion animals that resembles those reported in
human CCTs, where treatment efﬁcacy is as-
sessed by the dog owner several months after
the treatment had been given to the dog, seems
not to have been shown in veterinary clinical
studies.
The aim of this methodology study was to ex-
amine the need for and choice of stratiﬁcation
factors in the treatment of canine hip dysplasia,
and to investigate the effect of blinding and
placebo in a controlled clinical trial of pain
treatment in CHD.
Materials and methods
Animals
A total of 80 dogs recruited from all parts of
Norway, with pain and difﬁculty of movement
due to canine hip dysplasia (CHD), were in-
cluded in the study. The diagnosis of CHD was
based on radiographs and was graded as mild,
moderate or severe according to the guidelines
given by the Scientiﬁc Commission of the
Nordic Kennel Union and Federation Cyno-
logique Internationale. Dogs between one and
eight years of age, of both genders and all
breeds including mixed breeds, could partici-
pate. The reference population for the study
consisted of all family dogs in Norway. The
dogs were recruited through advertisement in
veterinary and breeder clubs' magazines. This
resulted in 47 females and 33 males whereof six
and one were neutered, respectively. Twenty-
eight breeds were represented. Dogs with other
diseases related to the nervous, muscular or
skeletal systems were excluded. Exclusion was
based on a thorough examination described be-
low under clinical procedure. Dogs with previ-
ous acupuncture experience were also excluded
from the study.
Study design
The study was carried out as a randomised
placebo-controlled and observer-blind clinical
trial with stratiﬁed parallel group design (Fig.
1). The main outcome parameter was change in
pain signs of CHD as assessed by the owner.
The stratiﬁcation factors used were body
weight in three groups and degree of CHD di-
agnosed by radiography divided into two
groups (mild/moderate CHD and severe CHD).
The design resulted in six strata. Within each
strata the patients were randomized to receive
either gold bead implantation or placebo once
in ratio 1:1 by using block randomization with
a ﬁxed blocksize of four. An error occurred dur-
ing classiﬁcation of cases, which resulted in an
unbalanced group in the stratum mild/moderate
hip dysplasia with body weight ≥35.0 kg, where
20 dogs were distributed 11: 9 in the placebo
group and the gold implantation group, respec-
tively. With a number of 20 dogs, ten dogs
should have been equally distributed in each
treatment group with a blocksize of four. A to-
tal of 38 dogs were treated blindly with gold
bead implantation and 42 with placebo (Table
1). The treatment was blinded for both the own-
ers and the responsible researcher during the
ﬁrst six months of the trial period, after which
the randomisation code was broken and the
placebo-treated dogs were offered gold bead
implantation. Of the 42 dogs in the placebo
group, 33 subsequently received gold bead im-
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out as an open study with a duration of further
18 months, and included both the dogs from the
blinded six month study and the open study
group. The total follow up period was therefore
24 months from the start of the study. 
In the blinded six-month period, two dogs from
the active group dropped out due to administra-
tive reasons (Table 1). In the 18 month follow
up period two of 36 dogs originally treated with
gold implantation dropped out due to adminis-
trative reasons and two discontinued for rea-
sons related to the treatment. Of the 33 dogs in
the placebo group that were given gold bead
implantation at the start of the 18 month follow
up period, one dropped out for reasons not re-
lated to the treatment, and three withdrew, two
of them for unknown reasons. The treatment re-
sults of the clinical trial have been reported
elsewhere (Jæger et al. 2004). 
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Figure 1. Flow chart of the study design of 80 dogs with different degrees of canine hip dysplasia (CHD) in-
cluded in a double blind randomized clinical trial.  The numbers (n) indicate the number of dogs within each
strata and randomized groups. (G) = Gold implantation group. (P) = Placebo group. (R) = Randomization pro-
cedure.Clinical procedure
At the enrolment consultation, the owner was
asked about the dog's clinical signs and medical
history using a standardized questionnaire.
Thereafter, all the dogs were thoroughly exam-
ined with special attention to the gait and move-
ment, the lumbar spine and muscles and the
skeleton of the hind limbs. The examination in-
cluded a neurological examination and hip ex-
tension test. All dogs were sedated and anes-
thetized, and then the coat was clipped over one
or both hips. A veterinarian certiﬁed in veteri-
nary acupuncture marked the acupuncture
points with one colour and marked another ﬁve
non-acupuncture points with a different colour.
The same veterinarian performed the clinical
examinations both initially and at every control
visit throughout the whole follow up period.
Hip radiographs were performed to conﬁrm the
diagnosis of CHD. Depending on their body
weight and radiographic hip score, the dogs
were assigned to one of six different strata.
Within each strata, dogs were randomly as-
signed a gold bead implantation or placebo in
accordance with a sealed pre-randomization
list. Another veterinarian specially trained in
the technique performed the gold bead implan-
tation through the acupuncture points, while
dogs allocated the placebo had the skin at the
non-acupuncture points penetrated with a nee-
dle of the same type and size as the one used for
gold bead implantation. 
The dogs were re-examined 14 days, three
months and six months after surgery. At the six
month visit the owners were asked what kind of
treatment, gold or placebo, they believed had
been given to their dog. The main outcome pa-
rameter, change in pain signs of CHD as as-
sessed by the owner, was recorded on a six
point ﬁxed scale (see Table 2). Participation
was free of charge and the owner signed a writ-
ten consent. The Norwegian Animal Research
Authority approved the study.
Statistical analysis
All the results were expressed in contingency
tables (Agresti 1990). Frequencies were ex-
pressed in percentages with 95% conﬁdence in-
tervals (CI) and calculated using the Binomial
distribution (Agresti 1990). 
Comparisons of groups were performed by cat-
egorical data analysis controlled for the actual
treatment given (Agresti 1990). In order to
study the contribution of the independent vari-
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Table 1. Number of dogs participating in a clinical controlled therapy trial of 80 dogs with different degrees of
canine hip dysplasia. The dogs were randomly assigned to receive either gold bead implantation or placebo in a
blinded 6-month study. The dogs in the placebo group were thereafter offered a crossover to gold bead implan-
tation, and all dogs were followed in an open trial for another 18 months.
Double blinded controlled Open clinical trial
clinical trial over six months Follow up18 months
Treatment Completed Drop out Withdrawal Completed Drop out Withdrawal
no. of dogs no. of dogs
Gold 36 2 0 32 2 2
Placebo 42 0 0 7 2 0
Gold, follow
up period * * * 29 1 3
Total 78 2 0 68 5 5
* = not applicable ables, a multiple regression analysis weighted
for the treatment given, based on a second-de-
gree polynome, was performed (Kleinbaum et
al. 1998). All hypotheses were tested two-
tailed, and differences were considered statisti-
cally signiﬁcant if the p-value was found to be
less than or equal to a level of 5%.
Results
On request, 63 of the 78 participating owners
blindly guessed the treatment given to their
dogs (Table 3). The probability of correctly
guessing the treatment was estimated to be
38/63 or 60% (CI 47.2-72.4%). The divergence
from the expected 50% was not signiﬁcant (p =
0.10). 
Twenty-two of the 30 owners guessed that gold
implantation had been given to their placebo
treated dogs, which is 73% (CI 54.1-87.7)
(Table 3). A total of 25 owners erroneously
guessed the treatment. Of those, 22 or 88% (CI
68.8 - 97.5%) believed the treatment given was
gold bead implantation, while three owners or
12% (CI 2.6-31.2%) guessed placebo. When
the owner guessed that gold was given they also
reported a greater improvement (p < 0.01) in
pain signs compared to those who guessed
placebo or were uncertain about the treatment
given (Table 4). No signiﬁcant difference in
change in pain signs reported by the owner was
found between these two last-mentioned
groups. Thus, a signiﬁcant placebo effect (p
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Table 2. Number of dogs with achieved treatment effect recorded as change in pain signs of canine hip dyspla-
sia (CHD) assessed by the owner, related to the two stratiﬁcation factors bodyweight and degree of CHD. Dis-
tribution of dogs according to the non-design stratum gender is also shown.
Pain signs of canine hip dysplasia Total
Factor Design Complete Large Mild No change Mild Large number 
strata recovery improvement improvement in signs aggravation aggravation of dogs
Body- 20.0 kg 0 3 1 1 0 1 6
weight 20.1-34.9 kg 5 14 5 9 2 3 38
35.0 kg 6 11 7 9 1 0 34
Canine Mild/ 6 14 7 11 2 0 40
hip moderate
dysplasia
S e v e r e51 4 6 81 43 8
Non-design
stratum
Gender Female 5 15 10 12 2 2 46
Male 6 13 3 7 1 2 32
Table 3. Owner's guess of treatment given versus ac-
tual treatment given and their prospective wishes re-
garding gold bead implantation for their dog in a clin-
ical controlled therapy trial of 80 dogs with canine
hip dysplasia. The two opinions of the owner were re-
quested at the end of the 6 month trial and before the
randomization code was broken. One dog owner per
dog expressed their opinion.
Wanted gold
Owner’s guess of Treatment implantation if not
treatment given actually given given previously
Placebo Gold Yes No
Placebo 8 3 11 0
Gold 22 30 35 17
Don't know 12 3 13 2<0.01) was detected (Table 3), and was sup-
ported by the ﬁndings presented in Table 4.
All the 11 owners who guessed that placebo
was given wanted gold bead implantation in
case of correct guessing (Table 3). Similar re-
sults were also found in the group of uncertain
owners. Of the 52 who believed that gold had
been implanted, 35 or 67% wanted gold im-
plantation if their dog belonged to the placebo
group. There was a signiﬁcant difference (p =
0.01) between the gold implantation group and
the placebo group with respect to the owner's
negative reply regarding further gold treatment
if their dog had ended up in the placebo group.
On the basis on prior knowledge, both body
weight and degree of CHD were chosen as
stratiﬁcation factors in the study design (Table
2). No signiﬁcant differences in the main out-
come parameter, when accounting for the ac-
tual treatment given, were detected for CHD (p
= 0.25) or body weight (p = 0.44). However, the
multiple regression analyses indicated that the
interactions between CHD and body weight
contributed signiﬁcantly to explain the im-
provement in pain signs.
Gender was tested as a possible stratiﬁcation
factor. No signiﬁcant difference was found be-
tween the genders (p = 0.59) in the main out-
come variable, change of pain signs (Table 2).
Age was found to have a signiﬁcant inﬂuence
on change in pain signs (Table 5). By dividing
the observed age distribution into quartiles, the
four age strata were deﬁned as ≤2.6 years, 2.7-
4.5 years, 4.6-5.9 years and ≥6.0 years. A nega-
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Table 4. Distribution of 78 dogs in a blinded clinical trial of canine hip dysplasia (CHD) with gold bead im-
plantation or placebo treatment according to the main outcome variable, change in pain signs of CHD, versus the
owner's guess of treatment given. The opinion of the owner was requested at the end of the blinded trial period
(six months), but before the randomization code was broken.
Owner's Pain signs of canine hip dysplasia
guess of Complete Large Mild No change Mild Large Total
treatment recovery improvement improvement in signs aggravation aggravation number 
given of dogs
Placebo 0 0 1 6 2 2 11
Gold 11 28 10 3 0 0 52
Don't know 0 0 2 10 1 2 15
Table 5. Estimated probability of improvement in pain signs of canine hip dysplasia related to four, three and
two age strata. The results are expressed in percent with 95% conﬁdence intervals. (n) = number of dogs.
Age strata Years Dogs (n) Probability of 95% conﬁdence p- values
improvement intervals
Four age ≤2.6  20 87.5 % 71.0% - 96.5% 0.057
strata 2.7 - 4.6 20 65.5 % 45.7% - 82.1%
4.7 - 5.9 20 57.7% 36.9% - 76.7%
≥6.0  18 74.1% 53.7% - 88.9%
Three ≤2.5  19 86.7% 69.3% - 96.2% 0.053 
age strata 2.6 - 6.0  41 63.2% 49.3% - 75.6% 
≥6.1  18 74.1% 53.7% - 88.9%
Two age ≤4.0  36 80.4% 67.6% - 89.8 % 0.047 
strata > 4.1  42 63.8% 50.1% - 76.0%tive linear correlation was found between age
and change in pain signs (r = - 0.14). A stronger
relationship was found using a second-degree
polynome (Fig. 2), leading to the following sug-
gested three age strata, ≤2.5 years, 2.6-6.0 years
and ≥6.1 years (Table 5). If only two age strata
are requested, an age = 4.0 years and >4.1 years
are suggested, based on the same linear regres-
sion analyses. 
After six months the randomization code was
broken, and the patients who previously re-
ceived a placebo now received gold bead im-
plantation as an open treatment. All the dogs
were followed for a further 18 months, and the
efﬁcacy was recorded additionally after six
months. The treatment efﬁcacy in pain signs in
the blinded study group of gold bead implanta-
tion was found to be signiﬁcantly larger com-
pared to the efﬁcacy obtained in the ﬁrst six
months during the open treatment (p = 0.02) in
the previous placebo group that received gold
bead implantation (Table 6).
Discussion
Several factors can affect the development of
canine hip dysplasia, and among them is body
weight (Kealy et al. 1997). We also know that
joint stability is inﬂuenced both by the amount
of muscle mass surrounding the joint and the
weight the joint must support (Cardinet, III et
64 G. T. Jæger et al.
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Figure 2. Regression analysis of age and pain signs in 80 dogs with canine hip dysplasia (CHD). The straight
line represents the linear relationship between the independent variable, age, and the dependent variable, change
in pain signs. The curved line indicates the relationship expressed by the second-degree polynome. Change in
signs of pain of CHD assessed by the owner was recorded by a six point ﬁxed scale where 1 = large aggravation,
2 = mild aggravation, 3 = no change in pain signs, 4 = mild improvement, 5 = large improvement and 6 = com-
plete recovery.al. 1997, Riser & Shirer 1967). In a comparable
study in humans (Davis et al. 1989), a signiﬁ-
cant correlation between obesity and bilateral
knee osteoarthritis was reported. In that study,
however, body weight itself was not found to
have any inﬂuence on treatment efﬁcacy unless
there was obesity and hence enhanced weight
load on the joint. As clinicians trained in the
causes of a speciﬁc disease, we can mistakenly
come to regard a cause as a factor that can in-
ﬂuence the outcome of a treatment. Although
we chose body weight as a stratiﬁcation factor,
this did not actually affect the outcome of the
study. 
Previous investigations have revealed a lack of
correlation between changes of the hip, deter-
mined radiographically, and the clinical signs
of hip dysplasia (Whittington et al. 1961, Riser
1973). However, to the best of our knowledge
no information exists on whether severe de-
grees of hip dysplasia are more difﬁcult to treat
than milder degrees. The interactions between
CHD and body weight apparently contributed
to explain the improvement in pain signs in this
study. Dogs with milder degrees of hip dyspla-
sia had a rising tendency of improvement in
pain signs with increasing body weight. The
opposite occurred with severe hip dysplasia, as
the improvement in pain signs decreased with
increasing body weight. However, the number
of dogs in the analysis was too small to provide
a conclusive interpretation.
Age and gender are two other possible stratiﬁ-
cation factors that could have been used in the
study design. We found that dogs younger than
2.6 years had the best effect of the treatment.
This is not surprising, since spontaneous im-
provement in limb function may occur as dogs
reach maturity (Riser 1973, Barr et al. 1987).
Due to this fact, one of the exclusion criteria
was dogs less than one year, even though many
dogs do not reach maturity until much later than
this age, depending on their ﬁnal size and de-
veloped muscle mass. This result was con-
ﬁrmed with multiple regression analysis, with
best improvement in pain signs in dogs less
than 2.5 years of age. This analysis also re-
vealed that dogs older than six years had an in-
creased improvement in pain signs. One possi-
ble explanation for this can be that dogs in this
study all were carefully selected and excluded if
other diseases were present. Additionally, there
may be a difference in the pathobiology be-
tween the dogs in the youngest and oldest age
groups when entering the study. Age is there-
fore a variable that may enhance the apparent
treatment effect, and is consequently recom-
mended as a stratiﬁcation factor.
The placebo effect is well documented in ani-
mal trials (Herrnstein 1962,  Batterman &
Lower 1968,  Phil & Altman 1971), and ex-
plained by Pavlovian conditioning. Studies of
the placebo effect have, however, been limited
primarily to laboratory animals in laboratory
environments, and animals living in a family
home under normal family conditions have
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Table 6. Distribution of 68 dogs according to change in pain signs of hip dysplasia (CHD) after gold bead im-
plantation in a controlled clinical trial of CHD.  The treatment effect for gold bead implantation is given in the
blinded trial versus the open treatment trial.
Pain signs of canine hip dysplasia Total
Treatment Complete Large Mild No change Mild Large number
recovery improvement improvement in signs aggravation aggravation of dogs 
Blinded gold 5 17 8 6 0 0 36
Open gold 1 14 9 2 4 2 32been poorly documented. The current study in-
dicated a signiﬁcant placebo effect, since sig-
niﬁcantly more owners guessed erroneously
that gold bead was given than placebo, and
since those who guessed that gold bead was
given reported more improvement in pain signs
than those who guessed that placebo was given. 
We assumed that owners, by taking the decision
to participate in a trial, would have a positive at-
titude towards a new and possibly controversial
treatment using gold bead implantation and
acupuncture, and this attitude was a potential
source of bias. One of the exclusion criteria was
therefore dogs with previous acupuncture expe-
rience. Another contribution to the placebo ef-
fect is a patient's expectation of the treatment
(Peck & Coleman 1991,  Feddersen-Petersen
1994). The owners' expectations of the treat-
ment effect can induce a placebo effect in both
treatment groups. It may also reﬂect what treat-
ment they believe has been given to their dogs,
since the owners' opinions were included in the
evaluation of the effect. This was conﬁrmed
when owners answered the question of whether
further gold treatment was desired or not. An-
other possible explanation of the improvement
in the placebo group is that dogs may discern
both their owner's signals (Gliedman et al.
1957) and also attitude towards the treatment,
the clinic and the veterinarian, and thereby give
their owners an impression of improvement or
aggravation. Dogs may behave differently due
to the owners' new signals and may also be en-
couraged to engage in forms of exercise that
they previously were spared for, but nonethe-
less, after a while were able to do without any
signs of pain.
When comparing the open versus blind studies,
the best effect was achieved in the blind study,
which is in accordance with other studies (Bat-
terman & Lower 1968,  Evans 1985). In the
blind study the placebo effect was included, and
in the open study probably the nocebo effect
was included. The true effect of the gold bead
treatment probably lay somewhere between
these two results.
Conclusion
Age seems to be the proper choice of stratiﬁca-
tion factor in therapy studies of canine hip dys-
plasia with a limited number (50-200) of par-
ticipating dogs. A signiﬁcant placebo effect
must be expected, and blinding and randomiza-
tion are necessary in studies where the outcome
of the treatment is based upon the owners' per-
ception of improvement of the clinical signs.
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Sammendrag
Stratiﬁsering, blinding og placeboeffekt i en ran-
domisert, dobbeltblind og placebokontrollert klinisk
undersøkelse av gullimplantasjon hos hunder med
hofteleddsdysplasi.
Hensikten med studien var å undersøke behovet for
og valget av stratiﬁseringsfaktorer, og effekten av
blinding og placebobehandling. Åtti hunder med
hofteleddsdysplasi (HD) ble inkludert i en ran-
domisert, placebokontrollert og dobbeltblind klinisk
undersøkelse med stratiﬁsert parallellgruppedesign.
Kroppsvekt og graden av HD ble valgt som stratiﬁ-
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Acta vet. scand. vol. 46 no. 1-2, 2005seringsfaktorer. Trettiåtte hunder ble trukket til en
engangs gullimplantasjonsbehandling og 42 hunder
ble trukket til placebobehandling. Etter seks måneder
(blindstudien) ﬁkk 33 av de 42 placebobehandlede
hundene gullimplantasjon i en åpen undersøkelse
som varte i ytterliggere 18 måneder. Behandlingsef-
fekten var den viktigste effektparameteren. Den ble
vurdert av eieren som endring i smertesymptomer fra
hofteleddsdysplasien. Ingen signiﬁkant forskjell i be-
handlingseffekt uavhengig av behandling ble funnet
med de to valgte stratiﬁseringsfaktorene. Alder var
den eneste faktoren som signiﬁkant inﬂuerte på be-
handlingseffekten. Seksti prosent av hundeeierne
gjettet korrekt på hvilken type behandling de trodde
hunden deres hadde fått. Blindingsprosedyren ble
derfor ansett som tilstrekkelig. Blant eierne som
gjettet feil trodde 88% at hundene hadde fått gull im-
plantert. Behandlingseffekten i blindstudien var
signiﬁkant bedre enn effekten i den åpne studien. En
signiﬁkant placeboeffekt ble funnet. Konklusjon og
klinisk relevans: Alderen til hundene påvirket utfallet
av behandlingen, og er derfor anbefalt som stratiﬁ-
seringsfaktor. En signiﬁkant placeboeffekt må for-
ventes, og en optimal blindingsprosedyre er derfor
nødvendig.
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